MedTrace Logo

Pharmacogenetics of Bupropion Metabolism

NCT00791869 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2013-05-22

No results posted yet for this study

Summary

The aim of the investigators research is to see if variants in a particular gene (named CYP2B6) affect how the body metabolizes (breaks down) certain medications, including the drug bupropion. Bupropion is widely used in the treatment of depression and for helping people quit smoking. Genes are portions of DNA that code for particular proteins in the body. The investigators are studying the gene that codes for a protein called CYP2B6. Differences in the structure of the gene are called variants and may mean that a person metabolizes a drug faster or slower than a person with a different variant.

Conditions

  • Metabolism
  • Pharmacokinetics

Sponsors & Collaborators

Principal Investigators

  • Neal L Benowitz, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-03-31
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791869 on ClinicalTrials.gov